Fibromyalgia: The nerve of that disease

Journal of Rheumatology

Volumn 32, Issue SUPPL. 75, 2005, Pages 29-37

  Levine, Jon D ^a   Reichling, David B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Fibromyalgia; Gastrointestinal tract; Pathologic processes; Vagus nerve

Indexed keywords

ALOSETRON; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; PRUCALOPRIDE; SEDATIVE AGENT; SEROTONIN 4 AGONIST; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; TEGASEROD;

ADRENERGIC SYSTEM; CHRONIC PAIN; CONFERENCE PAPER; FIBROMYALGIA; GASTROINTESTINAL TRACT; HUMAN; INTRACTABLE PAIN; IRRITABLE COLON; NEUROPATHY; PREDICTION; PRIORITY JOURNAL; SENSORY NERVE; SYMPTOMATOLOGY; VAGUS NERVE DISEASE; PATHOPHYSIOLOGY; REVIEW; STRESS; VAGUS NERVE;

FIBROMYALGIA; HUMANS; STRESS; VAGUS NERVE;

EID: 23444455317     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (175)

1. Buskila D, Neumann L, Hazanov I, Carmi R. Familial aggregation in the fibromyalgia syndrome. Semin Arthritis Rheum 1996;26:605-11.
2. Wolfe F, Ross K, Anderson J, Russell U, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19-28.
3. White KP, Harth M. Classification epidemiology and natural history of fibromyalgia. Curr Pain Headache Rep 2001;5:320-9.
4. Pillemer SR, Bradley LA, Crofford LJ, Moldofsky H, Chrousos GP. The neuroscience and endocrinology of fibromyalgia Arthritis Rheum 1997;40:1928-39.
5. Alagiri M, Chottiner S, Ratner V, Slade D, Hanno PM. Interstitial cystitis: unexplained associations with other chronic disease and pain syndromes. Urology 1997;49:52-7.
6. Wallace DJ. Genitourinary manifestations of fibrositis: an increased association with the female urethral syndrome. J Rheumatol 1990;17:238-9.
7. Burckhardt CS, Clark SR, Bennett RM. Fibromyalgia and quality of life: a comparative analysis. J Rheumatol 1993;20:475-9.
8. Cathey MA, Wolfe F, Kleinheksel SM. Fibrositis (fibromyalgia) in rheumatoid arthritis. J Rheumatol 1984;11:814-8.
9. Cathey MA, Wolfe F, Kleinheksel SM, Hawley DJ. Socioeconomic impact of fibrositis. A study of 81 patients with primary fibrositis. Am J Med 1986;81:78-84.
10. Hawley DJ, Wolfe F. Pain disability and pain/disability relationships in seven rheumatic disorders: a study of 1,522 patients. J Rheumatol 1991;18:1552-7.
11. Henriksson C, Gundmark I, Bengtsson A, Ek AC. Living with fibromyalgia. Consequences for everyday life. Clin J Pain 1992;8:138-44.
12. Henriksson CM. Longterm effects of fibromyalgia on everyday life. A study of 56 patients. Scand J Rheumatol 1994;23:36-41.
13. Wolfe F. Fibromyalgia: the clinical syndrome. Rheum Dis Clin North Am 1989;15:1-18.
14. Henriksson C, Burckhardt C. Impact of fibromyalgia on everyday life: a study of women in the USA and Sweden. Disabil Rehabil 1996;18:241-8.
15. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72.
16. Perle SM. Tender points/fibromyalgia vs trigger points/myofascial pain syndrome: a need for clarity in terminology and differential diagnosis. J Manipulative Physiol Ther 1996;19:146-7.
17. Aaron LA, Bradley LA, Alarcon GS, et al. Psychiatric diagnoses in patients with fibromyalgia are related to health care-seeking behavior rather than to illness. Arthritis Rheum 1996;39:436-45.
18. Bradley LA, Alarcon GS, Alexander RW, et al. Abnormal central processing of dolorimeter stimuli in patients and community residents with fibromyalgia: one year reliability [abstract]. Arthritis Rheum 1995;38 Suppl:S318.
19. Muller W, Lautenschlager J. Generalized tendomyopathy I: Clinical aspects follow-up and differential diagnosis. Z Rheumatol 1990;49:11-21.
20. Gibson SJ, Littlejohn GO, Gorman MM, Helme RD, Granges G. Altered heat pain thresholds and cerebral event-related potentials following painful CO2 laser stimulation in subjects with fibromyalgia syndrome. Pain 1994;58:185-93.
21. Kosek E, Ekholm J, Hansson P. Sensory dysfunction in fibromyalgia patients with implications for pathogenic mechanisms. Pain 1996;68:375-83.
22. Morris VH, Cruwys SC, Kidd BL. Evidence for abnormal pain processing in fibromyalgia [abstract]. Br J Rheumatol 1997;39:S389.
23. Norregaard J, Bendsten L, Lykkegaard J, Jensen R. Pressure and heat pain thresholds and tolerances in patients with fibromyalgia. J Musculoskeletal Pain 1997;5:43-53.
24. Jacobs JW, Rasker JJ, van der Heide A, et al. Lack of correlation between the mean tender point score and self-reported pain in fibromyalgia. Arthritis Care Res 1996;9:105-11.
25. Aaron LA, Buchwald D. Chronic diffuse musculoskeletal pain fibromyalgia and co-morbid unexplained clinical conditions. Best Pract Res Clin Rheumatol 2003;17:563-74.
26. Hudson JI, Goldenberg DL, Pope HG Jr, Keck PE Jr, Schlesinger L. Comorbidity of fibromyalgia with medical and psychiatric disorders. Am J Med 1992;92:363-7.
27. White KP, Speechley M, Harth M, Ostbye T. Co-existence of chronic fatigue syndrome with fibromyalgia syndrome in the general population. A controlled study. Scand J Rheumatol 2000;29:44-51.
28. Buskila D. Fibromyalgia, chronic fatigue syndrome, and myofascial pain syndrome. Curr Opin Rheumatol 2001;13:117-27.
29. Plesh O, Wolfe F, Lane N. The relationship between fibromyalgia and temporomandibular disorders: prevalence and symptom severity. J Rheumatol 1996;23:1948-52.
30. Hedenberg-Magnusson B, Ernberg M, Kopp S. Presence of orofacial pain and temporomandibular disorder in fibromyalgia. A study by questionnaire. Swed Dent J 1999;23:185-92.
31. Slotkoff AT, Radulovic DA, Clauw DJ. The relationship between fibromyalgia and the multiple chemical sensitivity syndrome. Scand J Rheumatol 1997;26:364-7.
32. Buchwald D, Garrity D. Comparison of patients with chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivities. Arch Intern Med 1994;154:2049-53.
33. Sivri A, Cindas A, Dincer F, Sivri B. Bowel dysfunction and irritable bowel syndrome in fibromyalgia patients. Clin Rheumatol 1996;15:283-6.
34. Triadafilopoulos G, Simms RW, Goldenberg DL. Bowel dysfunction in fibromyalgia syndrome. Dig Dis Sci 1991;36:59-64.
35. Veale D, Kavanagh G, Fielding JF, Fitzgerald O. Primary fibromyalgia and the irritable bowel syndrome: different expressions of a common pathogenetic process. Br J Rheumatol 1991;30:220-2.
36. Chang L. The association of functional gastrointestinal disorders and fibromyalgia. Eur J Surg Suppl 1998;583:32-6.
37. Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 2002;122:1140-56.
38. Sperber AD, Atzmon Y, Neumann L, et al. Fibromyalgia in the irritable bowel syndrome: studies of prevalence and clinical implications. Am J Gastroenterol 1999;94:3541-6.
39. Chang L, Mayer EA, Johnson T, FitzGerald LZ, Naliboff B. Differences in somatic perception in female patients with irritable bowel syndrome with and without fibromyalgia. Pain 2000;84:297-307.
40. Sperber AD, Carmel S, Atzmon Y, et al. Use of the Functional Bowel Disorder Severity Index (FBDSI) in a study of patients with the irritable bowel syndrome and fibromyalgia. Am J Gastroenterol 2000;95:995-8.
41. Fitzcharles MA, Esdaile JM. The overdiagnosis of fibromyalgia syndrome. Am J Med 1997;103:44-50.
42. Daoud KF, Barkhuizen A. Rheumatic mimics and selected triggers of fibromyalgia. Curr Pain Headache Rep 2002;6:284-8.
43. Buskila D, Odes LR, Neumann L, Odes HS. Fibromyalgia in inflammatory bowel disease. J Rheumatol 1999;26:1167-71.
44. Wolfe F, Cathey MA. Prevalence of primary and secondary fibrositis. J Rheumatol 1983;10:965-8.
45. Smets EM, Visser MR, Willems-Groot AF, Garssen B, Schuster-Uitterhoeve AL, de Haes JC. Fatigue and radiotherapy: (B) experience in patients 9 months following treatment. Br J Cancer 1998;78:907-12.
46. Van Andel G, Visser AP, Hulshof MC, Horenblas S, Kurth KH. Health-related quality of life and psychosocial factors in patients with prostate cancer scheduled for radical prostatectomy or external radiation therapy. BJU Int 2003;92:217-22.
47. Rivera J, de Diego A, Trinchet M, Garcia Monforte A. Fibromyalgia- associated hepatitis C virus infection. Br J Rheumatol 1997;36:981-5.
48. Killenberg PG. Extrahepatic manifestations of chronic hepatitis C. Semin Gastrointest Dis 2000;11:62-8.
49. Ruef C, Coleman DL. GM-CSF and G-CSF: cytokines in clinical application. Schweiz Med Wochenschr 1991;121:397-412.
50. Buckner JC, Burch PA, Cascino TL, O'Fallon JR, Scheithauer BW. Phase II trial of recombinant interferon-alpha-2a and eflornithine in patients with recurrent glioma. J Neurooncol 1998;36:65-70.
51. Petersen CS, Bjerring P, Larsen J, et al. Systemic interferon alpha-2b increases the cure rate in laser treated patients with multiple persistent genital warts: a placebo-controlled study. Genitourin Med 1991;67:99-102.
52. van West D, Macs M. Neuroendocrine and immune aspects of fibromyalgia. BioDrugs 2001;15:521-31.
53. Warner E, Keshavjeeal N, Shupak R, Bellini A. Rheumatic symptoms following adjuvant therapy for breast cancer. Am J Clin Oncol 1997;20:322-6.
54. Campbell SM, Clark S, Tindall EA, Forehand ME, Bennett RM. Clinical characteristics of fibrositis 1. A "blinded," controlled study of symptoms and tender points. Arthritis Rheum 1983;26:817-24.
55. Crofford LJ, Engleberg NC, Demitrack MA. Neurohormonal perturbations in fibromyalgia. Baillieres Clin Rheumatol 1996;10:365-78.
56. Geel SE. The fibromyalgia syndrome: musculoskeletal pathophysiology. Semin Arthritis Rheum 1994;23:347-53.
57. Uveges JM, Parker JC, Smarr KL, et al. Psychological symptoms in primary fibromyalgia syndrome: relationship to pain, life stress, and sleep disturbance. Arthritis Rheum 1990;33:1279-83.
58. Waylonis GW, Heck W. Fibromyalgia syndrome. New associations. Am J Phys Med Rehabil 1992;71:343-8.
59. Amir M, Kaplan Z, Neumann L, Sharabani R, Shani N, Buskila D. Posttraumatic stress disorder tenderness and fibromyalgia. J Psychosom Res 1997;42:607-13.
60. Affleck G, Urrows S, Tennen H, Higgins P, Abeles M. Sequential daily relations of sleep pain intensity and attention to pain among women with fibromyalgia. Pain 1996;68:363-8.
61. Hazlett RL, Haynes SN. Fibromyalgia: a time-series analysis of the stressor-physical symptom association. J Behav Med 1992;15:541-58.
62. Bennett RM, Clark SR, Goldberg L, et al. Aerobic fitness in patients with fibrositis. A controlled study of respiratory gas exchange and 133xenon clearance from exercising muscle. Arthritis Rheum 1989;32:454-60.
63. Klug GA, McAuley E, Clark S. Factors influencing the development and maintenance of aerobic fitness: lessons applicable to the fibrositis syndrome. J Rheumatol 1989;16 Suppl 19:30-9.
64. McCain GA, Bell DA, Mai FM, Halliday PD. A controlled study of the effects of a supervised cardiovascular fitness training program on the manifestations of primary fibromyalgia. Arthritis Rheum 1988;31:1135-41.
65. Wigers SH, Stiles TC, Vogel PA. Effects of aerobic exercise versus stress management treatment in fibromyalgia. A 4.5 year prospective study. Scand J Rheumatol 1996;25:77-86.
66. Fricton JR, Awad E. Myofascial pain and fibromyalgia. New York: Raven Press; 1990.
67. Kalyan-Raman UP, Kalyan-Raman K, Yunus MB, Masi AT. Muscle pathology in primary fibromyalgia syndrome: a light microscopic, histochemical, and ultrastructural study. J Rheumatol 1984;11:808-13.
68. Neeck G, Riedel W. Neuromediator and hormonal perturbations in fibromyalgia syndrome: results of chronic stress? Baillieres Clin Rheumatol 1994;8:763-75.
69. Crofford LJ. The hypothalamic-pituitary-adrenal stress axis in fibromyalgia and chronic fatigue syndrome. Z Rheumatol 1998;57:67-71.
70. Affleck G, Pfeiffer C, Tennen H, Fifield J. Attributional processes in rheumatoid arthritis patients. Arthritis Rheum 1987;30:927-31.
71. Wallace DJ. The role of stress and trauma in rheumatoid arthritis and systemic lupus erythematosus. Semin Arthritis Rheum 1987;16:153-7.
72. Crofford LJ, Pillemer SR, Kalogeras KT, et al. Hypothalamic-pituitary- adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum 1994;37:1583-92.
73. Griep EN, Boersma JW, de Kloet ER. Altered reactivity of the hypothalamic-pituitary-adrenal axis in the primary fibromyalgia syndrome. J Rheumatol 1993;20:469-74.
74. Lentjes EG, Griep EN, Boersma JW, Romijn FP, de Kloet ER. Glucocorticoid receptors, fibromyalgia, and low back pain. Psychoneuroendocrinology 1997;22:603-14.
75. Qiao ZG, Vaeroy H, Morkrid L. Electrodermal and microcirculatory activity in patients with fibromyalgia during baseline acoustic stimulation and cold pressor tests. J Rheumatol 1991;18:1383-9.
76. van Denderen JC, Boersma JW, Zeinstra P, Hollander AP, van Neerbos BR. Physiological effects of exhaustive physical exercise in primary fibromyalgia syndrome (PFS): is PFS a disorder of neuroendocrine reactivity? Scand J Rheumatol 1992;21:35-7.
77. Raj SR, Brouillard D, Simpson CS, Hopman WM, Abdollah H. Dysautonomia among patients with fibromyalgia: a noninvasive assessment. J Rheumatol 2000;27:2660-5.
78. Cohen H, Neumann L, Alhosshle A, Kotler M, Abu-Shakra M, Buskila D. Abnormal sympathovagal balance in men with fibromyalgia. J Rheumatol 2001;28:581-9.
79. Martinez-Lavin M, Hermosillo AG, Mendoza C, et al. Orthostatic sympathetic derangement in subjects with fibromyalgia. J Rheumatol 1997;24:714-8.
80. Bornstein SR, Ehrhart-Bornstein M, Scherbaum WA, Pfeiffer EF, Holst JJ. Effects of splanchnic nerve stimulation on the adrenal cortex may be mediated by chromaffin cells in a paracrine manner. Endocrinology 1990;127:900-6.
81. Dallman MF. Control of adrenocortical growth in vivo. Endocr Res 1984;10:213-42.
82. Ehrhart-Bornstein M, Bornstein SR, Gonzalez-Hernandez J, Hoist JJ, Waterman MR, Scherbaum WA. Sympathoadrenal regulation of adrenocortical steroidogenesis. Endocr Res 1995;21:13-24.
83. Ehrhart-Bornstein M, Hinson JP, Bornstein SR, Scherbaum WA, Vinson GP. Intraadrenal interactions in the regulation of adrenocortical steroidogenesis. Endocr Rev 1998;19:101-43.
84. Barden N. Modulation of glucocorticoid receptor gene expression by antidepressant drugs. Pharmacopsychiatry 1996;29:12-22.
85. Brady LS, Whitfield HJ Jr, Fox RJ, Gold PW, Herkenham M. Long-term antidepressant administration alters corticotropin-releasing hormone tyrosine hydroxylase and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications. J Clin Invest 1991;87:831-7.
86. Eisenhofer G, Friberg P, Goldstein DS, Esler M. Differential actions of desipramine on sympathoadrenal release of noradrenaline and adrenaline. Br J Clin Pharmacol 1995;40:263-5.
87. Ikeda Y, Nomura S, Sawa Y, Nakazawa T. The effects of antidepressants on the autonomic nervous system - a current investigation. J Neural Transm 1982;54:65-73.
88. Reul JM. Stec I, Soder M, Holsboer F. Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic- pituitary-adrenocortical system. Endocrinology 1993;133:312-20.
89. Rowe W, Steverman A, Walker M, et al. Antidepressants restore hypothalamic-pituitary-adrenal feedback function in aged cognitively-impaired rats. Neurobiol Aging 1967;18:527-33.
90. Shaver JL, Lentz M, Landis CA, Heitkemper MM, Buchwald DS, Woods NF. Sleep psychological distress and stress arousal in women with fibromyalgia. Res Nurs Health 1997;20:247-57.
91. Torpy DJ, Grice JE, Hockings GI, Crosbie GV, Walters MM, Jackson RV. The effect of desipramine on basal and naloxone-stimulated cortisol secretion in humans: interaction of two drugs acting on noradrenergic control of adrenocorticotropin secretion. J Clin Endocrinol Metab 1995;80:802-6.
92. Yeragani VK, Srinivasan K, Pohl R, Berger R, Balon R, Ramesh C. Effects of nortriptyline on heart rate variability in panic disorder patients: a preliminary study using power spectral analysis of heart rate. Neuropsychobiology 1994;29:1-7.
93. Buskila D. Drug therapy. Baillieres Best Pract Res Clin Rheumatol 1999;13:479-85.
94. Lautenschlager J. Present state of medication therapy in fibromyalgia syndrome. Scand J Rheumatol Suppl 2000;113:32-6.
95. Forseth KK, Gran JT. Management of fibromyalgia: what are the best treatment choices? Drugs 2002;62:577-92.
96. Belilos E, Carsons S. Rheumatologic disorders in women. Med Clin North Am 1998;82:77-101.
97. Bradley LA, Alarcon GS. Fibromyalgia. In: Koopman WJ, editor. Arthritis and allied conditions: a textbook of rheumatology. Baltimore: Williams & Wilkins; 1997.
98. Bennett RM. A raw vegetarian diet for patients with fibromyalgia. Curr Rheumatol Rep 2002;4:284.
99. Busch A, Schachter CL, Peloso PM, Bombardier C. Exercise for treating fibromyalgia syndrome. Cochrane Database Syst Rev 2002;3:CD003786.
100. Kaartinen K, Lammi K, Hypen M, Nenonen M, Hanninen O, Rauma AL. Vegan diet alleviates fibromyalgia symptoms. Scand J Rheumatol 2000;29:308-13.
101. Sim J, Adams N. Systematic review of randomized controlled trials of nonpharmacological interventions for fibromyalgia. Clin J Pain 2002;18:324-36.
102. Leventhal LJ. Management of fibromyalgia. Ann Intern Med 1999;131:850-8.
103. Sorensen J, Bengtsson A, Ahlner J, Henriksson KG, Ekselius L, Bengtsson M. Fibromyalgia - are there different mechanisms in the processing of pain? A double blind crossover comparison of analgesic drugs. J Rheumatol 1997;24:1615-21.
104. The use of opioids for the treatment of chronic pain. A consensus statement from the American Academy of Pain Medicine and the American Pain Society. Clin J Pain 1997;13:6-8.
105. Portenoy RK. Opioid therapy for chronic nonmalignant pain: a review of the critical issues. J Pain Symptom Manage 1996;11:203-17.
106. Miller LJ, Kubes KL. Serotonergic agents in the treatment of fibromyalgia syndrome. Ann Pharmacother 2002;36:707-12.
107. Egbunike IG, Chaffee BJ. Antidepressants in the management of chronic pain syndromes. Pharmacotherapy 1990;10:262-70.
108. Gear RW, Miaskowski C, Gordon NC, Paul SM, Heller PH, Levine JD. The kappa opioid nalbuphine produces gender- and dose-dependent analgesia and antianalgesia in patients with postoperative pain. Pain 1999;83:339-45.
109. Spath M. Current experience with 5-HT3 receptor antagonists in fibromyalgia. Rheum Dis Clin North Am 2002;28:319-28.
110. Muller W, Stratz T. Results of the intravenous administration of tropisetron in fibromyalgia patients. Scand J Rheumatol 2000;113 Suppl:59-62.
111. Haus U, Varga B, Stratz T, Spath M, Muller W. Oral treatment of fibromyalgia with tropisetron given over 28 days: influence on functional and vegetative symptoms psychometric parameters and pain. Scand J Rheumatol 2000;113:Suppl 55-8.
112. Farber L, Stratz T, Bruckle W, et al. Efficacy and tolerability of tropisetron in primary fibromyalgia - a highly selective and competitive 5-HT3 receptor antagonist. German Fibromyalgia Study Group. Scand J Rheumatol 2000;113:Suppl 49-54.
113. Bennet RM, Clark SR, Campbell SM, Burkhardt CS. Low levels of somatomedin C in patients with the fibromyalgia syndrome. A possible link between sleep and muscle pain. Arthrits Rheum 1992;35:1113-1
114. Bennett RM. Fibromyalgia and the disability dilemma. A new era in understanding a complex multidimensional pain syndrome. Arthritis Rheum 1996;39:1627-34.
115. Yunus MB. Towards a model of pathophysiology of fibromyalgia: aberrant central pain mechanisms with peripheral modulation. J Rheumatol 1992;19:846-50.
116. Sann H, Pierau FK. Efferent functions of C-fiber nociceptors. Z Rheumatol 1998;57:8-13.
117. Arroyo JF, Cohen ML. Abnormal responses to electrocutaneous stimulation in fibromyalgia. J Rheumatol 1993;20:1925-31.
118. Sorensen J, Bengtsson A, Backman E, Henriksson KG, Bengtsson M. Pain analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocaine, and ketamine. Scand J Rheumatol 1995;24:360-5.
119. Lautenbacher S, Rollman GB. Possible deficiencies of pain modulation in fibromyalgia. Clin J Pain 1997;13:189-96.
120. Khasar SG, Miao FJ, Janig W, Levine JD. Vagotomy-induced enhancement of mechanical hyperalgesia in the rat is sympathoadrenal-mediated. J Neurosci 1998;18:3043-9.
121. Khasar SG, Miao JP, Janig W, Levine JD. Modulation of bradykinin-induced mechanical hyperalgesia in the rat by activity in abdominal vagal afferents. Eur J Neurosci 1998;10:435-44.
122. Federspil G, Baggio B, De Palo C, De Carlo E, Borsatti A, Vettor R. Effect of prolonged physical exercise on muscular phospholipase A2 activity in rats. Diabete Metab 1987;13:171-5.
123. Kurita A, Takase B, Maruyama T, et al. Plasma bradykinin and prostaglandin metabolism and exercise testing in patients with silent myocardial ischemia compared with patients with painful myocardial ischemia. Jpn Circ J 1989;53:1466-71.
124. Rett K, Wicklmayr M, Dietze GJ. Metabolic effects of kinins: historical and recent developments. J Cardiovasc Pharmacol 1990;15:557-9.
125. Jaeger B, Skootsky SA. Double blind controlled study of different myofascial trigger point injection technique [abstract]. Pain 1987;31:S292.
126. Bengtsson M, Bengtsson A, Jorfeldt L. Diagnostic epidural opioid blockade in primary fibromyalgia at rest and during exercise. Pain 1989;39:171-80.
127. Acasuso-Diaz M, Collantes-Estevez E. Topical capsaicin versus ketoprofen in primary fibromyalgia syndrome [abstract]. Br J Rheumatology 1998;37:s151.
128. Littlejohn GO, Weinstein C, Helme RD. Increased neurogenic inflammation in fibrositis syndrome. J Rheumatol 1987;14:1022-5.
129. Smythe HA, Moldofsky H. Two contributions to understanding of the "fibrositis" syndrome. Bull Rheum Dis 1977;28:928-31.
130. Backman E, Bengtsson A, Bengtsson M, Lennmarken C, Henriksson KG. Skeletal muscle function in primary fibromyalgia. Effect of regional sympathetic blockade with guanethidine. Acta Neurol Scand 1988;77:187-91.
131. Bengtsson A, Bengtsson M. Regional sympathetic blockade in primary fibromyalgia. Pain 1988;33:161-7.
132. Henriksson KG, Bengtsson A. Fibromyalgia - a clinical entity? Can J Physiol Pharmacol 1991;69:672-7.
133. Iadarola MJ, Max MB, Berman KF, et al. Unilateral decrease in thalamic activity observed with positron emission tomography in patients with chronic neuropathic pain. Pain 1995;63:55-64.
134. Mountz JM, Bradley LA, Modell JG, et al. Fibromyalgia in women. Abnormalities of regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low pain threshold levels. Arthritis Rheum 1995;38:926-38.
135. Simms RW, Goldenberg DL. Symptoms mimicking neurologic disorders in fibromyalgia syndrome. J Rheumatol 1988;15:1271-3.
136. Andrews PL. Irritable bowel syndrome: just a pain in the butt? Gastroenterology 1994;107:1886-90.
137. Andrews PL. Modulation of visceral afferent activity as a therapeutic possibility for gastrointestinal disorders. In: Read NW, editor. Irritable bowel syndrome: New ideas and insights into pathophysiology. Oxford: Blackwell Science; 1991.
138. Coffin B, Azpiroz F, Guarner F, Malagelada JR. Selective gastric hypersensitivity and reflex hyporeactivity in functional dyspepsia. Gastroenterology 1994;107:1345-51.
139. Dawson AM. Origin of pain in the irritable bowel syndrome. In: Read NW, editor. Irritable bowel syndrome. London: Grune & Stratton; 1985.
140. Doran FS. The sites to which pain is referred from the common bile-duct in man and its implication for the theory of referred pain. Br J Surg 1967;54:599-606.
141. Kingham JG, Dawson AM. Origin of chronic right upper quadrant pain. Gut 1985;26:783-8.
142. Whitehead WE, Holtkotter B, Enck P, et al. Tolerance for rectosigmoid distention in irritable bowel syndrome. Gastroenterology 1990;98:1187-92.
143. Dailey PA, Bishop GD, Russell IJ, Fletcher EM. Psychological stress and the fibrositis/fibromyalgia syndrome. J Rheumatol 1990;17:1380-5.
144. Yunus M, Masi AT, Calabro JJ, Miller KA, Feigenbaum SL. Primary fibromyalgia fibrositis: clinical study of 50 patients with matched normal controls. Semin Arthritis Rheum 1981;11:151-71.
145. Crofford LJ. Neuroendocrine abnormalities in fibromyalgia and related disorders. Am J Med Sci 1998;315:359-66.
146. Wurtman RJ. Stress and the adrenocortical control of epinephrine synthesis. Metabolism 2002;51:11-4.
147. Randich A, Gebhart GF. Vagal afferent modulation of nociception. Brain Res Rev 1992;17:77-99.
148. Watkins LR, Wiertelak EP, Goehler LE, et al. Neurocircuitry of illness-induced hyperalgesia. Brain Res 1994;639:283-99.
149. Papka RE, Srinivasan B. Miller KE, Hayashi S. Localization of estrogen receptor protein and estrogen receptor messenger RNA in peripheral autonomic and sensory neurons. Neuroscience 1997;79:1153-63.
150. Bond EF, Heitkemper MM, Perigo R. Gastric emptying and gastric-intestinal transit in rats with varying ovarian hormone status. Nurs Res 1996;45:218-24.
151. Khasar SG, Green PG, Gear RW, Isenberg W, Levine JD. Gonadal hormones do not account for sexual dimorphism in vagal modulation of nociception in the rat. J Pain 2003;4:190-6.
152. Khasar SG, Miao FJ, Gear RW, Green PG, Levine JD. Vagal modulation of bradykinin-induced mechanical hyperalgesia in the female rat. J Pain 2003;4:278-83.
153. Zukowska-Grojec Z, Shen GH, Capraro PA, Vaz CA. Cardiovascular neuropeptide Y and adrenergic responses in stress are sexually differentiated. Physiol Behav 1991;49:771-7.
154. DeTurck KH, Vogel WH. Factors influencing plasma catecholamine levels in rats during immobilization. Pharmacol Biochem Behav 1980;13:129-31.
155. Livezey GT, Miller JM, Vogel WH. Plasma norepinephrine epinephrine and corticosterone stress responses to restraint in individual male and female rats and their correlations. Neurosci Lett 1985;62:51-6.
156. Taylor J, Weyers P, Harris N, Vogel WH. The plasma catecholamine stress response is characteristic for a given animal over a one-year period. Physiol Behav 1989;46:853-6.
157. Ng AV, Callister R, Johnson DG, Seals DR. Age and gender influence muscle sympathetic nerve activity at rest in healthy humans. Hypertension 1993;21:498-503.
158. Kirschbaum C, Schommer N, Federenko I, et al. Short-term estradiol treatment enhances pituitary-adrenal axis and sympathetic responses to psychosocial stress in healthy young men. J Clin Endocrinol Metab 1996;81:3639-43.
159. Staud R. Evidence of involvement of central neural mechanisms in generating fibromyalgia pain. Curr Rheumatol Rep 2002;4:299-305.
160. Bradley LA, McKendree-Smith NL. Central nervous system mechanisms of pain in fibromyalgia and other musculoskeletal disorders: behavioral and psychologic treatment approaches. Curr Opin Rheumatol 2002;14:45-51.
161. Staud R, Smitherman ML. Peripheral and central sensitization in fibromyalgia: pathogenetic role. Curr Pain Headache Rep 2002;6:259-66.
162. Khasar SG, Green PG, Miao FJP, Levine JD. Vagal modulation of nociception is mediated by adrenomedullary epinephrine in the rat. Eur J Neurosci 2003;17:909-15.
163. Schwartz GJ, Moran TH. Sub-diaphragmatic vagal afferent integration of meal-related gastrointestinal signals. Neurosci Biobehav Rev 1996;20:47-56.
164. Schwartz GJ, McHugh PR, Moran TH. Pharmacological dissociation of responses to CCK and gastric loads in rat mechanosensitive vagal afferents. Am J Physiol 1994;267:R303-8.
165. Holzer HH, Turkelson CM, Solomon TE, Raybould HE. Intestinal lipid inhibits gastric emptying via CCK and a vagal capsaicin-sensitive afferent pathway in rats. Am J Physiol 1994;267:G625-9.
166. Bluthe RM, Michaud B, Kelley KW, Dantzer R. Vagotomy blocks behavioural effects of interleukin-1 injected via the intraperitoneal route but not via other systemic routes. Neuroreport 1996;7:2823-7.
167. Laye S, Bluthe RM, Kent S, et al. Subdiaphragmatic vagotomy blocks induction of IL-1 beta mRNA in mice brain in response to peripheral LPS. Am J Physiol 1995;268:R1327-31.
168. Watkins LR, Maier SF, Goehler LE. Immune activation: the role of pro-inflammatory cytokines in inflammation illness responses and pathological pain states. Pain 1995;63:289-302.
169. Hansen MK, Krueger JM. Subdiaphragmatic vagotomy blocks the sleep- and fever-promoting effects of interleukin-1 beta. Am J Physiol 1997;273:R1246-53.
170. Opp MR, Toth LA. Somnogenic and pyrogenic effects of interleukin-1 beta and lipopolysaccharide in intact and vagotomized rats. Life Sci 1998;62:923-36.
171. Aronoff GM. Myofascial pain syndrome and fibromyalgia: a critical assessment and alternate view. Clin J Pain 1998;14:74-85.
172. Jacobsen S, Petersen IS, Danneskiold-Samsoe B. Clinical features in patients with chronic muscle pain - with special reference to fibromyalgia. Scand J Rheumatol 1993;22:69-76.
173. Miao FJ, Janig W, Green PG, Levine JD. Inhibition of bradykinin-induced plasma extravasation produced by noxious cutaneous and visceral stimuli and its modulation by vagal activity. J Neurophysiol 1997;78:1285-92.
174. Cohen H, Neumann L, Shore M, Amir M, Cassuto Y, Buskila D. Autonomic dysfunction in patients with fibromyalgia: application of power spectral analysis of heart rate variability. Semin Arthritis Rheum 2000;29:217-27.
175. Tougas G. The autonomic nervous system in functional bowel disorders. Can J Gastroenterol 1999;13 Suppl A:15A-17A.